Lento Bio raised $680,000 aiming to restore near vision in presbyopia patients
Lento Bio - 06-Sep-2022Ichor Life Sciences leads the investment to advance anti-glycation therapies
Join the club for FREE to access the whole archive and other member benefits.
Company that develops clinical products in the field of regenerative medicine
Since its founding in 2013, Ichor has studied fundamental mechanisms of aging to develop new classes of drugs dedicated to helping people live longer, healthier lives.
Building a successful company is a consequence of what we do in the pursuit of our vision. We are intrinsically motivated to create positive change in the world because we believe we can.
Ichor operates from its corporate offices and research laboratories in rural LaFayette, NY (just south of Syracuse). The company is eager to engage collaborators and clients in industry and academia who share its vision of delivering next generation therapies for the illnesses of aging.
Visit website: https://www.ichortherapeutics.com/
Details last updated 04-May-2019
CEO of Ichor Therapeutics focussed on drug discovery that impacts the pathways of aging
Ichor Life Sciences leads the investment to advance anti-glycation therapies
Lento Bio research into molecular aging damage by accelerating clinical assets
Even if supplement really contains C60 it's likely to have degraded into toxic species
Indications are less clear with anti-ageing compounds than with disease specific drugs
Has cleared protein build up in vivo - has funding to develop clinical candidates
$16m raided, FoxBio partnership with Juvenescence, lots going on
Encouraging signs from big companies - more interviews to follow
Ichor Therapeutics is a biotechnology company focused on developing drugs for age-related disease...
It is focused on the twofold path of (a) establishing patient-funded trials of potentially usefu...